About SINO BIOPHARM Company

China Biopharmaceuticals Co., Ltd. (“the Company” or “China Biopharmaceuticals”) and its subsidiaries (the “Group”) are China's leading innovative research and development-driven pharmaceutical group. Its business covers the entire industry chain with pharmaceutical R&D platforms, intelligent production and strong sales systems. The products include a variety of biopharmaceuticals and chemical drugs, and are in an advantageous position in the four major treatment fields of oncology, liver disease, respiratory system, and surgery/analgesia. The Company was listed on the Hong Kong Stock Exchange in 2000, selected as a constituent stock of the MSCI Global Standard Index in 2013; selected as a constituent stock of the Hang Seng Index in 2018; selected as a constituent stock of the Hang Seng China Enterprise Index in 2019; selected as a constituent stock of the Hang Seng Shanghai, Shenzhen and Hong Kong Stock Connect Biotechnology 50 Index and the Hang Seng China (Hong Kong Listed) 25 Index in 2020. For five consecutive years, China Biopharmaceuticals has been ranked in the “Top 50 Global Pharmaceutical Companies” published by the authoritative American magazine “Pharmaceutical Manager”, and for three consecutive years, it has been named “Top 50 Best Companies in Asia Pacific” by “Forbes” (Asia). Chinese biopharmaceuticals companies are located in Beijing, Shanghai, Nanjing, Lianyungang, Qingdao, etc., and have multiple pharmaceutical production bases. Since its establishment, the company has continued to achieve outstanding achievements and steady development. The core member companies, Zhengda Tianqing Pharmaceutical Group Co., Ltd. and Beijing Tide Pharmaceutical Co., Ltd. have all ranked among the top 100 enterprises in the Chinese pharmaceutical industry for many years. The company takes imitation as the cornerstone, fully transforms to innovation, drives growth with innovative drugs, and increases revenue share year by year; internal research pipelines drive innovation and transformation and continuously improve the technology platform; under the leadership of top scientific teams, we actively promote the internationalization process and seize the leading international race track. China Biopharmaceuticals will adhere to the mission of “health technology, warm more lives”, focus on innovation, serve patients, and strive to become the world's leading pharmaceutical company. We hope to share the development achievements of the medical and health industry with people of insight, cooperate vigorously, and win the future together!